Further studies on ALL revealed that PON2 mRNA levels were significantly higher in B-ALL compared with normal pre-B cells, with elevated enzyme expression being a potential predictor of unfavorable clinical outcomes in both pediatric and adult B-ALL patients. The gene discussed is PON2; the disease is acute lymphoblastic leukemia.